Market Place
Sourcing Support
XOMA Royalty Reports Q2 2024 Results And Recent Activities
13 Aug 2024 //
GLOBENEWSWIRE
XOMA Corporation Announces Closing of Tender Offer
03 Apr 2024 //
GLOBENEWSWIRE
XOMA Announces Expiration Date for Tender Offer for Kinnate Biopharma Inc.
19 Mar 2024 //
GLOBENEWSWIRE
Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre
05 Mar 2024 //
PRESS RELEASE
Kinnate Sells Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre
01 Mar 2024 //
PR NEWSWIRE
Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre
01 Mar 2024 //
GLOBENEWSWIRE
XOMA Enters into Agreement to Acquire Kinnate Biopharma
16 Feb 2024 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Kinnate lays off 70% of staff, pulls back from programs
19 Sep 2023 //
FIERCE BIOTECH
Kinnate Biopharma Inc. Announces Pipeline Updates
18 Sep 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib
17 Apr 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Adds Two New Drug Candidates to Its Growing Targeted Oncology
17 Apr 2023 //
GLOBENEWSWIRE
Kinnate Adds Two Drug Candidates to Its Growing Targeted Oncology Pipeline
17 Apr 2023 //
PRESS RELEASE
Kinnate Biopharma touts early efficacy in pan-RAF program
17 Apr 2023 //
ENDPTS
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Kinnate to Report First Data for Investigational Pan-RAF Inhibitor, Exarafenib
14 Mar 2023 //
GLOBENEWSWIRE
Kinnate buys OrbiMed`s stake in cancer JV to go solo in China
22 Feb 2023 //
FIERCE BIOTECH
Kinnate Announces Acquisition from Series A Investors of Kinnjiu
21 Feb 2023 //
GLOBENEWSWIRE
Kinnate Receives Fast Track Designation from the U.S. FDA for KIN-3248,
14 Feb 2023 //
GLOBENEWSWIRE
Kinnate to Participate in the 2023 SVB Securities Global Biopharma Conference
06 Feb 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Appointed Jill DeSimone as Independent Director
26 Jan 2023 //
GLOBENEWSWIRE
Kinnate to Present Trials in Progress Poster for Pan-FGFR Inhibitor, KIN-3248
17 Jan 2023 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Announces 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Kinnate Announces Recent Corporate Updates, Including on the Ongoing KIN-2787
11 Oct 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Receives Fast Track Designation from the USFDA for KIN-2787
21 Sep 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit
15 Sep 2022 //
GLOBENEWSWIRE
Kinnate Biopharma to Participate in the 2022 Wells Fargo Securities Healthcare
30 Aug 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Announces Q2 2022 Rusult and Recent Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
Kinnate Bio to Participate in 2022 Wedbush PacGrow Healthcare Virtual Conference
02 Aug 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
01 Jun 2022 //
GLOBENEWSWIRE
Kinnate Biopharma to Present Trial Design for KIN-3248, at ASCO 2022
26 May 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Begins Dosing in PI Trial of KIN-3248
18 Apr 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Shows Data from KIN-2787, RAF Clinico-Genomics Studies at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Kinnate Bio Reports Full Year 2021 Financial Results and Operational Updates
28 Mar 2022 //
GLOBENEWSWIRE
Kinnate Biopharma says Acceptance of Abstracts for Presentation at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Presents Data from its Real-World Clinico-Genomic Study
07 Mar 2022 //
GLOBENEWSWIRE
Kinnate Biopharma to Participate in the 42nd Annual Cowen Health Care Conference
28 Feb 2022 //
GLOBENEWSWIRE
Kinnate Biopharma to Deliver Oral Presentation on RAF Inhibitor Program
14 Feb 2022 //
GLOBENEWSWIRE
Kinnate Biopharma to Participate in 11th Annual SVB Leerink Global Conference
07 Feb 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Announces FDA Clearance of IND for KIN-3248
18 Jan 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Provides Corporate Update, Highlights Upcoming 2022 Milestones
06 Jan 2022 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor
20 Dec 2021 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index
17 Dec 2021 //
GLOBENEWSWIRE
Kinnate Biopharma Presents Preclinical Data on its Lead FGFR Inhibitor Candidate
13 Sep 2021 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Kinnate Biopharma to Participate in the William Blair Biotech Focus Conference
07 Jul 2021 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
28 Jun 2021 //
GLOBENEWSWIRE
KINNATE BIOPHARMA REPORTS FDA CLEARANCE OF IND APPLICATION FOR KIN-2787
17 May 2021 //
CMLVIZ
Kinnate, OrbiMed team up to target Chinese lung cancer market
14 May 2021 //
FIERCEBIOTECH
Kinnate Biopharma Closes $35 M Series A to Establish a Chinese Joint Venture
13 May 2021 //
GLOBENEWSWIRE
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase
10 May 2021 //
BUSINESSWIRE
Kinnate Biopharma to Present Pre-Clinical Data from its RAF Kinase Inhibitor
10 May 2021 //
BIOSPACE
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
19 Mar 2021 //
GLOBENEWSWIRE
Kinnate gets $98 million Series C to push precision oncology drugs to the clinic
25 Aug 2020 //
ENDPTS
